The role of N-methyl-d-aspartate receptor subunit NR2B in spinal cord in cancer pain

European Journal of Pain

Volumn 14, Issue 5, 2010, Pages 496-502

  Gu, XiaoPing ^a   Zhang, Juan ^a   Ma, ZhengLiang ^a   Wang, JunHua ^a   Zhou, XiaoFang ^a   Jin, YanQing ^a   Xia, XiaoPing ^a   Gao, Qin ^a   Mei, FengMei ^a  

^a THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

Author keywords

Cancer pain; Ifenprodil; Mouse model; NMDA receptor; NR2B

Indexed keywords

IFENPRODIL; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B;

ALLODYNIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BONE CANCER; CANCER PAIN; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; EVOKED RESPONSE; GENE EXPRESSION; HYPERALGESIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SPINAL CORD; TISSUE DISTRIBUTION;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; BONE NEOPLASMS; CELL LINE, TUMOR; CELLS, CULTURED; HYPERALGESIA; IMMUNOHISTOCHEMISTRY; MICE; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; PIPERIDINES; RANDOM ALLOCATION; RECEPTORS, N-METHYL-D-ASPARTATE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPINAL CORD; TIME FACTORS;

EID: 77951880112     PISSN: 10903801     EISSN: 15322149     Source Type: Journal    
DOI: 10.1016/j.ejpain.2009.09.001     Document Type: Article

References (49)

1. Abe T., Matsumura S., Katano T., Mabuchi T., Takagi K., Xu L., et al. Fyn kinase-mediated phosphorylation of NMDA receptor NR2B subunit at Tyr1472 is essential for maintenance of neuropathic pain. Eur J Neurosci 22 6 (2005) 1445-1454
2. Banning A., Sjogren P., and Henriksen H. Pain causes in 200 patients referred to a multidisciplinary cancer pain clinic. Pain 45 1 (1991) 45-48
3. Bernardi M., Bertolini A., Szczawinska K., and Genedani S. Blockade of the polyamine site of NMDA receptors produces antinociception and enhances the effect of morphine, in mice. Eur J Pharmacol 298 (1996) 51-55
4. Boyce S., Wyatt A., Webb J.K., O'Donnell R., Mason G., Rigby M., et al. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn. Neuropharmacology 38 5 (1999) 611-623
5. Campbell-Fleming J.M., and Williams A. The use of ketamine as adjuvant therapy to control severe pain. Clin J Oncol Nurs 12 1 (2008) 102-107
6. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., and Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53 1 (1994) 55-63
7. Clarke R.W. Synaptic mechanisms in nociception: emerging targets for centrally-acting analgesics. Emerg Ther Targets 4 (2000) 173-189
8. Felsby S., Nielsen J., Arendt-Nielsen L., and Jensen T.S. NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride. Pain 64 2 (1996) 283-291
9. Finkel J.C., Pestieau S.R., and Quezado Z.M.N. Ketamine as an adjuvant for treatment of cancer pain in children and adolescents. J Pain 8 6 (2007) 515-521
10. Guo W., Wei F., Zou S., Robbins M.T., Sugiyo S., Ikeda T., et al. Group I metabotropic glutamate receptor NMDA receptor coupling and signaling cascade mediate spinal dorsal horn NMDA receptor 2B tyrosine phosphorylation associated with inflammatory hyperalgesia. J Neurosci 24 41 (2004) 9161-9173
11. Hama A., Woon Lee J., and Sagen J. Differential efficacy of intrathecal NMDA receptor antagonists on inflammatory mechanical and thermal hyperalgesia in rats. Eur J Pharmacol 459 1 (2003) 49-58
12. Hargreaves K., Dubner R., Brown F., Flores C., and Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32 1 (1988) 77-88
13. Honore P., Rogers S.D., Schwei M.J., Salak-Johnson J.L., Luger N.M., Sabino M.C., et al. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in spinal cord and sensory neurons. Neuroscience 98 3 (2000) 585-598
14. Hylden J.L., and Wilcox G.L. Intrathecal morphine in mice: a new technique. Eur J Pharmacol 67 2-3 (1980) 313-316
15. Iwata H., Takasusuki T., Yamaguchi S., and Hori Y. NMDA receptor 2B subunit-mediated synaptic transmission in the superficial dorsal horn of peripheral nerve-injured neuropathic mice. Brain Res 1135 1 (2007) 92-101
16. Khasabov S.G., Hamamoto D.T., Harding-Rose C., and Simone D.A. Tumor-evoked hyperalgesia and sensitization of nociceptive dorsal horn neurons in a murine model of cancer pain. Brain Res 1180 (2007) 7-19
17. Klein T., Magerl W., Hanschmann A., Althaus M., and Treede R.D. Antihyperalgesic and analgesic properties of the N-methyl-d-aspartate (NMDA) receptor antagonist neramexane in a human surrogate model of neurogenic hyperalgesia. Eur J Pain 12 1 (2008) 17-29
18. Loftis J.M., and Janowsky A. The N-methyl-d-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. Pharmacol Ther 97 1 (2003) 55-85
19. Lynch D.R., Lawrence J.J., Lenz S., Anegawa N.J., Dichter M., and Pritchett D.B. Pharmacological characterization of heterodimeric NMDA receptors composed of NR 1a and 2B subunits: differences with receptors formed from NR 1a and 2A. J Neurochem 64 (1995) 1462-1468
20. Ma Q.P., and Hargreaves R.J. Localization of N-methyl-d-aspartate NR2B subunits on primary sensory neurons that give rise to small-caliber sciatic nerve fibers in rats. Neuroscience 101 3 (2000) 699-707
21. Ma Z.L., Zhang W., Gu X.P., Yang W.S., and Zeng Y. Effects of intrathecal injection of prednisolone acetate on expression of NR2B Subunit and nNOS in spinal cord of rats after chronic compression of dorsal root ganglia. Ann Clin Lab Sci 37 4 (2007) 349-355
22. Mantyh PW. A mechanism-based understanding of bone cancer pain. In: Novartis found symp, vol. 261; 2004. p. 194-214 (discussion 214-9, 256-61).
23. Martino D., Tamasdan C., Moryl N., and Inturrist C. Concurrent use of ketamine and methadone in severe cancer pain. J Pain 9 4 Suppl 1 (2008) 24
24. McBain C.J., and Mayer M.L. N-methyl-d-aspartic acid receptor structure and function. Physiol Rev 74 3 (1994) 723-760
25. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 69 1-2 (1997) 1-18
26. Mercadante S. Recent progress in the pharmacotherapy of cancer pain. Expert Rev Anticancer Ther 1 3 (2001) 487-494
27. Meuser T., Pietruck C., Radbruch L., Stute P., Lehmann K.A., and Grond S. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 93 3 (2001) 247-257
28. Monyer H., Sprengel R., Schoepfer R., Herb A., Higuchi M., Lomeli H., et al. Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science 256 5060 (1992) 1217-1221
29. Monyer H., Burnashev N., Laurie D.J., Sakmann B., and Seeburg P.H. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12 3 (1994) 529-540
30. Nagy G.G., Watanabe M., Fukaya M., and Todd A.J. Synaptic distribution of the NR1, NR2A and NR2B subunits of the N-methyl-d-aspartate receptor in the rat lumbar spinal cord revealed with an antigen-unmasking technique. Eur J Neurosci 20 12 (2004) 3301-3312
31. Nikolajsen L., Gottrup H., Kristensen A.G.D., and Jensen T.S. Memantine (a N-methyl-d-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: a randomized, double-blinded, cross-over study. Anesth Analg 91 (2000) 960-966
32. Parsons C.G., Danysz W., and Quack G. Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect 11 9 (1997) 523-569
33. Parsons C.G. NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol 429 (2001) 71-78
34. Peng W.L., Wu G.J., Sun W.Z., Chen J.C., and Huang A.T. Multidisciplinary management of cancer pain: a longitudinal retrospective study on a cohort of end-stage cancer patients. J Pain Symptom Manage 32 5 (2006) 444-452
35. Portenoy R.K., and Lesage P. Management of cancer pain. Lancet 353 9165 (1999) 1695-1700
36. Portenoy R.K., Payne D., and Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81 1-2 (1999) 129-134
37. Saito O., Aoe T., Kozikowski A., Sarva J., Neale J.H., and Yamamoto T. Ketamine and N-acetylaspartylglutamate peptidase inhibitor exert analgesia in bone cancer pain. Can J Anaesth 53 9 (2006) 891-898
38. Schwei M.J., Honore P., Rogers S.D., Salak-Johnson J.L., Finke M.P., Ramnaraine M.L., et al. Neurochemical and cellular reorganization of spinal cord in a murine model of bone cancer pain. J Neurosci 19 24 (1999) 10886-10897
39. Sevcik M.A., Ghilardi J.R., Peters C.M., Lindsay T.H., Halvorson K.G., Jonas B.M., et al. Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain 115 (2005) 128-141
40. Soliman A.C., Yu J.S.C., and Coderre T.J. MGlu and NMDA receptor contributions to capsaicin-induced thermal and mechanical hypersensitivity. Neuropharmacology 48 3 (2005) 325-332
41. Suzuki R., and Dickenson A. Spinal and supraspinal contributions to central sensitization in peripheral neuropathy. Neurosignals 14 (2005) 175-181
42. Tan P.H., Yang L.C., Shih H.C., Lan K.C., and Cheng J.T. Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat. Gene Ther 12 1 (2005) 59-66
43. Taniguchi K., Shinjo K., Mizutani M., Shimada K., Ishikawa T., Menniti F.S.S., et al. Antinociceptive activity of CP-101, 606, an NMDA receptor NR2B subunit antagonist. Br J Pharmacol 122 (1997) 809-812
44. Ultenius C., Linderoth B., Meyerson B.A., and Wallin J. Spinal NMDA receptor phosphorylation correlates with the presence of neuropathic signs following peripheral nerve injury in the rat. Neurosci Lett 399 1-2 (2006) 85-90
45. Urch C.E., Donovan-Rodriguez T., and Dickenson A.H. Alterations in dorsal horn neurons in a rat model of cancer-induced bone pain. Pain 106 (2003) 347-356
46. Williams K. Ifenprodil discriminates subtypes of the N-methyl-d-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Mol Pharmacol 44 (1993) 851-859
47. Wilson J.A., Garry E.M., Anderson H.A., Rosie R., Colvin L.A., Mitchell R., et al. NMDA receptor antagonist treatment at the time of nerve injury prevents injury-induced changes in spinal NR1 and NR2B subunit expression and increases the sensitivity of residual pain behaviours to subsequently administered NMDA receptor antagonists. Pain 117 3 (2005) 421-432
48. Woolf C.J., and Salter M.W. Neuronal plasticity: increasing the gain in pain. Science 288 (2000) 1765-1768
49. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16 2 (1983) 109-110